Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $5.07B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $4.81M in total
- 3
- 13F holdersQ2 2026, +30 vs. previous quarter
- 269
- 13F valueReported value at the end of Q2 2026
- $6.40B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.04M
- −67.3% year over year
- Net income, FY2025
- -$162.3M
- No comparable prior period
- Free cash flow, FY2025
- -$129.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $12.1M
- +2,966.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $162.3M (7973.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 8.99M
- Shares sold short
- Change
- −153.6K
- −1.7% vs. previous
- Days to cover
- 10.17
- At average daily volume
Superinvestors holding DNTH, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DNTH at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Dianthus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:36 PM ET | Sep 17 | 1 day | Carr EdwardCHIEF ACCOUNTING OFFICER | SSale | −20.0K | $101.38 | −$2.03M | −100.0%0 after | 5 lots10b5-1 |
| Sep 3, 2026 (view filing)4:30 PM ET | Sep 1 | 2 days | Randhawa SimratEVP, Head of R&D | SSale | −23.1K | $106.41 | −$2.46M | −85.3%4.00K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)6:02 PM ET | Aug 19 | Same day | Read SimonDirector | SSale | −2.78K | $117.55 | −$326.6K | −100.0%0 after | 10b5-1 |
| Aug 11, 2026 (view filing)5:15 PM ET | Aug 10 | 1 day | McGeorge AnneDirector | SSale | −7.75K | $109.01 | −$844.8K | −100.0%0 after | 5 lots10b5-1 |
| Aug 11, 2026 (view filing)5:10 PM ET | Aug 10 | 1 day | Read SimonDirector | SSale | −2.78K | $109.55 | −$304.2K | −100.0%0 after | 6 lots10b5-1 |
| Aug 11, 2026 (view filing)5:08 PM ET | Aug 7-10 | 4 days | Veness Adam MSVP, General Counsel and Sec. | SSale | −20.0K | $110.44 | −$2.21M | −100.0%0 after | 3 lots10b5-1 |
| Aug 7, 2026 (view filing)6:30 PM ET | Aug 7 | Same day | Garcia MarinoCEO AND PRESIDENT | SSale | −166.0K | $108.11 | −$17.9M | −71.8%65.3K after | 7 lots10b5-1 |
| Jul 13, 2026 (view filing)5:00 PM ET | Jul 9 | 4 days | Savitz RyanEVP, CFO & CBO | SSale | −31.2K | $101.03 | −$3.16M | −100.0%0 after | 3 lots10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −30.0K | $80.80 | −$2.42M | −100.0%0 after | 2 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Randhawa SimratEVP, Head of R&D | SSale | −26.5K | $90.62 | −$2.40M | −86.9%4.00K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 269 holdersThe largest institutional positions in Dianthus Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 8,199,893 | $799.3M | 0.03% | +432,207+5.6% | Added |
| BlackRock, Inc. | 4,123,822 | $402.0M | 0.01% | +948,119+29.9% | Added |
| T. Rowe Price Investment Management, Inc. | 3,888,456 | $379.0M | 0.25% | +2,596,274+200.9% | Added |
| Wellington Management Group LLP | 3,229,882 | $314.8M | 0.05% | +634,099+24.4% | Added |
| Fairmount Funds Management LLC | 2,537,191 | $247.3M | 16.35% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 2,514,946 | $245.2M | 0.02% | +1,367,998+119.3% | Added |
| State Street Corp | 2,357,440 | $229.8M | 0.01% | +958,527+68.5% | Added |
| Vanguard Capital Management LLC | 2,159,568 | $210.5M | 0.00% | +128,319+6.3% | Added |
| Avidity Partners Management LP | 2,104,184 | $205.1M | 32.85% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 1,841,667 | $179.5M | 16.48% | −105,000−5.4% | Reduced |
Holders of 5% or more of DNTH
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Dianthus Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%5.97M shares | +1.00 ppfrom 14.00% | Nov 13, 20233 filings | Nov 5, 2025 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 12.10%6.63M shares | +5.00 ppfrom 7.10% | Aug 7, 20262 filings | Aug 7, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.40%3.50M shares | +1.30 ppfrom 5.10% | Oct 24, 20245 filings | Jul 28, 2026 | SEC |
| Wellington Management Group LLP | 13G | 5.90%3.23M shares | +1.10 ppfrom 4.80% | Nov 12, 20253 filings | Aug 13, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.08%2.85M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |